OneMedNet (ONMD)
OneMedNet on one page: short interest, daily short volume, fails to deliver, large holders, financials and insider trades. Listed on Nasdaq, classified by the SEC as services-commercial physical & biological research.
114K
Short interest
settlement 2026-09-30
1.2
Days to cover
-3.4 days vs prior
35.2%
Short share of volume
2026-10-09
5,771
Fails to deliver
settlement 2026-09-03
$987K
Insider flow, 90 days
2 buys, 5 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in ONMD is 113,555 shares, down 763,015 shares over the last month. Over the last 48 readings it ranged from 28,009 shares (30 April 2025) to 3,275,592 shares (15 August 2025). The latest reading sits at the bottom of that range. At the reported average volume of 94K shares a day that is 1.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/onmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 113,555 | -87.7% | 94,253 | 1.20 |
| 2026-09-15 | 922,431 | +5.2% | 198,376 | 4.65 |
| 2026-08-31 | 876,570 | +21.4% | 342,431 | 2.56 |
| 2026-08-14 | 721,823 | -60.3% | 666,106 | 1.08 |
| 2026-07-31 | 1,816,220 | +425.7% | 3,840,358 | 1.00 |
| 2026-07-15 | 345,502 | +48.4% | 125,694 | 2.75 |
| 2026-06-30 | 232,816 | -54.2% | 501,081 | 1.00 |
| 2026-06-15 | 508,235 | +11.1% | 317,044 | 1.60 |
| 2026-05-29 | 457,290 | -18.0% | 278,774 | 1.64 |
| 2026-05-15 | 557,591 | -25.0% | 311,808 | 1.79 |
| 2026-04-30 | 743,681 | +20.0% | 1,456,585 | 1.00 |
| 2026-04-15 | 619,780 | -18.1% | 314,216 | 1.97 |
| 2026-03-31 | 757,167 | -56.0% | 342,638 | 2.21 |
| 2026-03-13 | 1,720,441 | +446.8% | 1,479,468 | 1.16 |
| 2026-02-27 | 314,631 | -3.8% | 24,146,172 | 1.00 |
| 2026-02-13 | 326,990 | +45.8% | 283,072 | 1.16 |
| 2026-01-30 | 224,270 | +65.8% | 313,084 | 1.00 |
| 2026-01-15 | 135,229 | +0.4% | 387,625 | 1.00 |
| 2025-12-31 | 134,674 | -68.2% | 484,008 | 1.00 |
| 2025-12-15 | 423,841 | +93.6% | 763,417 | 1.00 |
| 2025-11-28 | 218,963 | +83.9% | 4,893,900 | 1.00 |
| 2025-11-14 | 119,084 | -55.2% | 338,836 | 1.00 |
| 2025-10-31 | 265,662 | -61.9% | 794,006 | 1.00 |
| 2025-10-15 | 697,808 | -1.6% | 31,230,041 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of ONMD volume is 35.2%, up 6.2 points over the last five sessions. Over the last 30 readings it ranged from 7.5% (23 September 2026) to 78.7% (6 October 2026). The latest reading is 3.5 points above the 30-session average of 31.7%, on 12K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 4K | 12K | 35.2% | 90 |
| 2026-10-08 | 2K | 7K | 20.6% | 0 |
| 2026-10-07 | 6K | 18K | 32.3% | 0 |
| 2026-10-06 | 21K | 27K | 78.7% | 0 |
| 2026-10-05 | 4K | 15K | 27.1% | 0 |
| 2026-10-02 | 6K | 20K | 29.0% | 0 |
| 2026-10-01 | 19K | 29K | 66.0% | 0 |
| 2026-09-30 | 50K | 82K | 61.1% | 10,812 |
| 2026-09-29 | 17K | 55K | 31.2% | 5,379 |
| 2026-09-28 | 161K | 311K | 51.9% | 17,735 |
| 2026-09-25 | 172K | 501K | 34.3% | 58,516 |
| 2026-09-24 | 35K | 109K | 31.6% | 0 |
| 2026-09-23 | 10K | 135K | 7.5% | 0 |
| 2026-09-22 | 279K | 579K | 48.3% | 214,508 |
| 2026-09-21 | 57K | 206K | 27.7% | 29,280 |
| 2026-09-18 | 348K | 873K | 39.9% | 852 |
| 2026-09-17 | 13K | 35K | 36.1% | 0 |
| 2026-09-16 | 7K | 45K | 14.4% | 0 |
| 2026-09-15 | 24K | 82K | 29.7% | 0 |
| 2026-09-14 | 37K | 145K | 25.4% | 0 |
| 2026-09-11 | 20K | 103K | 19.3% | 0 |
| 2026-09-10 | 5K | 31K | 15.2% | 0 |
| 2026-09-09 | 10K | 51K | 19.6% | 0 |
| 2026-09-08 | 26K | 232K | 11.2% | 0 |
| 2026-09-04 | 90K | 299K | 30.2% | 0 |
| 2026-09-03 | 49K | 155K | 31.7% | 0 |
| 2026-09-02 | 27K | 61K | 43.6% | 0 |
| 2026-09-01 | 7K | 45K | 16.2% | 0 |
| 2026-08-31 | 19K | 125K | 15.4% | 0 |
| 2026-08-28 | 13K | 67K | 19.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 3 September 2026, the fails-to-deliver balance in ONMD is 5,771 shares, down 14,180 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (24 April 2026) to 684,602 shares (18 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-03 | 5,771 | $0.57 | $3K |
| 2026-09-01 | 19,951 | $0.59 | $12K |
| 2026-08-27 | 2,233 | $0.57 | $1K |
| 2026-08-21 | 4,207 | $0.59 | $2K |
| 2026-08-12 | 3,549 | $0.74 | $3K |
| 2026-08-10 | 33,235 | $0.62 | $21K |
| 2026-08-05 | 4 | $0.71 | $3 |
| 2026-08-04 | 1,782 | $0.76 | $1K |
| 2026-08-03 | 1,307 | $0.72 | $941 |
| 2026-07-31 | 125,193 | $0.73 | $91K |
| 2026-07-30 | 172,906 | $0.64 | $111K |
| 2026-07-29 | 235,927 | $0.71 | $168K |
| 2026-06-30 | 19,677 | $0.71 | $14K |
| 2026-06-26 | 5 | $0.59 | $3 |
| 2026-06-24 | 12,309 | $0.60 | $7K |
| 2026-06-18 | 684,602 | $0.60 | $411K |
| 2026-06-17 | 337,262 | $0.50 | $169K |
| 2026-06-16 | 283,500 | $0.56 | $159K |
| 2026-06-15 | 135,400 | $0.54 | $73K |
| 2026-06-08 | 5,058 | $0.68 | $3K |
| 2026-06-03 | 195,281 | $0.79 | $154K |
| 2026-05-13 | 393 | $0.97 | $381 |
| 2026-05-08 | 7,523 | $0.98 | $7K |
| 2026-05-07 | 8,772 | $0.96 | $8K |
| 2026-05-05 | 25,533 | $1.05 | $27K |
| 2026-05-04 | 16,972 | $1.00 | $17K |
| 2026-04-30 | 94,331 | $1.08 | $102K |
| 2026-04-28 | 45,925 | $1.20 | $55K |
| 2026-04-27 | 27,448 | $1.10 | $30K |
| 2026-04-24 | 2 | $0.89 | $2 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONOver the last 90 days ONMD insiders reported 2 open-market buys ($1.1M) against 5 sells ($103K), so the dollar flow leans toward buying. Latest filing: Green Aaron (Chief Executive Officer) on 2026-09-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Green Aaron | Chief Executive Officer | Sell | 2K | $6.48 | $11K | 248K |
| 2026-09-22 | Green Aaron | Chief Executive Officer | Sell | 5K | $7.39 | $37K | 250K |
| 2026-09-21 | Golden Robert Lawrence | Chief Financial Officer | Sell | 3K | $6.63 | $20K | 91K |
| 2026-09-15 | Golden Robert Lawrence | Chief Financial Officer | Sell | 3K | $6.30 | $19K | 94K |
| 2026-09-14 | Golden Robert Lawrence | Chief Financial Officer | Sell | 3K | $6.60 | $17K | 97K |
| 2026-09-10 | Yu Jeffrey | Chief Medical Officer | Buy | 143K | $0.63 | $90K | 8.9M |
| 2026-07-30 | Kosasa Thomas | Director, 10% owner | Buy | 1.4M | $0.69 | $1000K | 18.5M |
| 2026-07-06 | Green Aaron | Chief Executive Officer | Grant | 65K | $0.00 | $0 | 255K |
| 2026-07-06 | Golden Robert Lawrence | Chief Financial Officer | Grant | 35K | $0.00 | $0 | 100K |
| 2026-06-23 | Yu Jeffrey | Chief Medical Officer | Buy | 159K | $0.63 | $100K | 8.8M |
| 2026-06-23 | Green Aaron | Chief Executive Officer | Buy | 37K | $0.57 | $21K | 1.9M |
| 2026-06-16 | Yu Jeffrey | Chief Medical Officer | Buy | 172K | $0.58 | $100K | 8.6M |
| 2026-06-15 | Green Aaron | Chief Executive Officer | Buy | 19K | $0.54 | $10K | 1.9M |
| 2026-06-12 | Kosasa Thomas | Director,TenPercentOwner | Buy | 159K | $0.63 | $100K | 17.1M |
| 2026-06-12 | Green Aaron | Chief Executive Officer | Buy | 37K | $0.56 | $21K | 1.8M |
| 2026-05-18 | Kosasa Thomas | Director, 10% owner | Buy | 269K | $0.93 | $250K | 16.9M |
| 2026-04-23 | Kosasa Thomas | Director, 10% owner | Buy | 281K | $0.89 | $250K | 16.7M |
| 2026-04-01 | Yu Jeffrey | Chief Medical Officer | Grant | 219K | $0.83 | $182K | 8.4M |
| 2026-04-01 | Yu Jeffrey | Chief Medical Officer | Buy | 904K | $0.83 | $750K | 8.2M |
| 2026-02-06 | Kosasa Thomas | Director, 10% owner | Buy | 595K | $0.84 | $500K | 16.4M |
| 2026-01-01 | Golden Robert Lawrence | Chief Financial Officer | Grant | 10K | $0.00 | $0 | 65K |
| 2025-11-26 | Yu Jeffrey | Chief Medical Officer | Grant | 45K | $0.00 | $0 | 7.3M |
| 2025-11-26 | Zeinfeld Andrew B | Director | Grant | 45K | $0.00 | $0 | 382K |
| 2025-11-26 | McCraw Sherry Coonse | Director | Grant | 45K | $0.00 | $0 | 56K |
| 2025-11-26 | Kosasa Thomas | Director | Grant | 45K | $0.00 | $0 | 15.8M |
| 2025-11-26 | Green Aaron | Chief Executive Officer | Grant | 45K | $0.00 | $0 | 1.9M |
| 2025-11-26 | Golden Robert Lawrence | Chief Financial Officer | Grant | 45K | $0.00 | $0 | 548K |
| 2025-11-26 | Clarke Jair | Director | Grant | 45K | $0.00 | $0 | 138K |
| 2025-11-26 | Casaburi Eric | Director | Grant | 45K | $0.00 | $0 | 110K |
| 2025-11-26 | Alleyne Kenneth | Director | Grant | 38K | $0.00 | $0 | 38K |
| 2025-11-24 | Yu Jeffrey | Chief Medical Officer | Grant | 200K | $0.00 | $0 | 7.3M |
| 2025-11-24 | Green Aaron | Chief Executive Officer | Grant | 1.0M | $0.00 | $0 | 1.9M |
| 2025-11-24 | Golden Robert Lawrence | Chief Financial Officer | Grant | 33K | $0.00 | $0 | 503K |
| 2025-11-24 | Golden Robert Lawrence | Chief Financial Officer | Grant | 300K | $0.00 | $0 | 470K |
| 2025-11-18 | Green Aaron | Chief Executive Officer | Sell | 62K | $1.20 | $74K | 1.8M |
| 2025-10-22 | Green Aaron | Chief Executive Officer | Sell | 65K | $2.23 | $145K | 1.9M |
| 2025-10-15 | Casaburi Eric | Director | Buy | 10K | $3.05 | $31K | 65K |
| 2025-09-25 | Yu Jeffrey | Chief Medical Officer | Buy | 1K | $1.03 | $1K | 7.1M |
| 2025-09-24 | Yu Jeffrey | Chief Medical Officer | Buy | 17K | $1.02 | $18K | 7.1M |
| 2025-09-24 | Kosasa Thomas | Director | Buy | 6K | $0.93 | $6K | 15.7M |
| 2025-09-23 | Yu Jeffrey | Chief Medical Officer | Buy | 6K | $0.93 | $5K | 7.1M |
| 2025-09-22 | Yu Jeffrey | Chief Medical Officer | Buy | 400 | $0.95 | $380 | 7.1M |
| 2025-09-19 | Yu Jeffrey | Chief Medical Officer | Buy | 1K | $0.89 | $1K | 7.1M |
| 2025-09-18 | Yu Jeffrey | Chief Medical Officer | Buy | 700 | $0.91 | $637 | 7.1M |
| 2025-09-05 | Yu Jeffrey | Chief Medical Officer | Buy | 2K | $0.86 | $2K | 7.1M |
| 2025-09-04 | Yu Jeffrey | Chief Medical Officer | Buy | 12K | $0.87 | $10K | 7.1M |
| 2025-09-03 | Yu Jeffrey | Chief Medical Officer | Buy | 12K | $0.81 | $9K | 7.0M |
| 2025-09-02 | Yu Jeffrey | Chief Medical Officer | Buy | 24K | $0.85 | $21K | 7.0M |
| 2025-08-29 | Yu Jeffrey | Chief Medical Officer | Buy | 11K | $0.82 | $9K | 7.0M |
| 2025-08-29 | Kosasa Thomas | Director | Buy | 581K | $0.86 | $500K | 15.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ONMD in its latest filing, on Schedule 13G (passive). The holder is TD SECURITIES (USA) LLC at 6.2% of the class (3,025,338 shares), filed 2025-11-14 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2025-11-14 | 13G/Ano. 1 | ROBERT K. CITRONEparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | DISCOVERY GLOBAL OPPORTUNITY MASTER FUND, LTD.corporation | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | DISCOVERY CAPITAL MANAGEMENT, LLCinvestment adviser | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | TD SECURITIES (USA) LLCbroker-dealer | 3.0M | 6.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | TORONTO DOMINION HOLDINGS USA INCparent holding company | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | TD GROUP US HOLDINGS LLCparent holding company | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | TORONTO DOMINION BANKnon-US institution | 0 | 0.0% | 2025-09-30 |
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2027 (quarter ended 2026-06-30) OneMedNet reported revenue of $292K, up 88.4% from the same quarter a year earlier, and net loss of $2.2M (-0.04 diluted EPS). In FY 2024 it generated -$4.8M of operating cash flow. As of 2026-06-30, cash was $358K against $132K of debt.
- Cash
- $358K
- Debt
- $132K
- Equity
- -$3.5M
- Total assets
- $1.4M
- Shares outstanding
- 59,286,450
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2027 | 2026-06-30 | $292K | -$2.2M | -743.8% | -0.04 |
| Q1 FY 2027 | 2026-03-31 | $96K | -$2.5M | -2555.2% | -0.04 |
| Q3 FY 2026 | 2025-09-30 | $177K | -$741K | -418.6% | -0.01 |
| Q2 FY 2026 | 2025-06-30 | $155K | $3.0M | 1923.9% | 0.07 |
| Q1 FY 2026 | 2025-03-31 | $137K | -$1.9M | -1388.3% | -0.06 |
| Q3 FY 2025 | 2024-09-30 | $142K | -$2.1M | -1449.3% | -0.07 |
| Q2 FY 2025 | 2024-06-30 | $227K | -$3.6M | -1581.1% | -0.14 |
| Q1 FY 2025 | 2024-03-31 | $248K | -$2.1M | -850.4% | -0.08 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2024 | 2023-12-31 | $1.0M | -$33.8M | -$4.8M | $44K | n/a | n/a |
| FY 2023 | 2022-12-31 | $1.2M | -$30.5M | -$4.7M | $58K | n/a | n/a |
| FY 2022 | 2021-12-31 | n/a | $5.1M | -$378K | n/a | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-11 from the cover page.
What this page is
OneMedNet in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows OneMedNet (ONMD), SEC CIK 1849380, listed on Nasdaq, classified by the SEC as services-commercial physical & biological research. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-03.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2025-11-14.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1849380Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-commercial physical & biological research
Other company pages
Datasets
Frequently Asked Questions
How much of ONMD is sold short?
What is ONMD's daily short volume?
Does ONMD have fails to deliver?
Are ONMD insiders buying or selling?
Who owns 5% or more of ONMD?
What did ONMD report last quarter?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.